A cancer drug licensed by GSK from China has delivered promising results in a trial, in a boost for the company’s oncology strategy.
The FTSE 100 group said Mo-Rez had an “objective response rate” — the percentage of patients whose cancer disappeared or shrank — of 62 per cent in ovarian cancer and 67 per cent in endometrial cancer. In these patients, their tumours shrank by at least 30 per cent.
A review of 85 cancer drugs approved by the US Food and Drug Administration between 2006 and 2018 found a median response rate of 41 per cent.
您已阅读16%（540字），剩余84%（2824字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。